In this cohort, preliminary data has been reported with 7% unconfirmed RR in 27 evaluable patients, however further data will be required to determine the efficacy for the EGFR exon 20 insertion NSCLC subgroup. This evidence concerns the gene EGFR and non-small cell lung carcinoma.